About Intercept Pharmaceuticals
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.
In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.
Our corporate headquarters is located in New Jersey.
For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on Twitter at: @InterceptPharma.
|
|
|
201-500 employees
View all Intercept Pharmaceuticals employees
|
|
Pharmaceuticals
|
|
305 Madison Ave, Morristown, New Jersey 07960, US
|
|
2002
|
|
Biotechnology, Innovation, Rare Diseases, Non-Viral Liver Diseases
|
Intercept Pharmaceuticals Alternatives
Frequently Asked Questions about Intercept Pharmaceuticals
Anindita Sinha is the CEO of Intercept Pharmaceuticals. To contact Anindita Sinha email at [email protected].
The decision makers in Intercept Pharmaceuticals are Brian Canestraro, Deryk David, Dick Lancaster, etc. Click to Find Intercept Pharmaceuticals decision makers emails.
Intercept Pharmaceuticals Staff Directory
Search Intercept Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
